Laboratory and Pathology Mergers & Acquisition Activity: How Recent Sales and The Current Economy Could Impact the Value of Your Lab
The economic downturn has certainly made a big difference in laboratory merger & acquisition (M&A) activity. While we saw record prices for clinical labs and pathology practices in 2008, pricing and demand have been tempered by the economic changes in 2009. But it’s not all bad news. If you’ve been holding off selling your lab, the wait could be over.
But here’s a way to find out for sure.
Haverford Healthcare Advisors
Richard Cooper, Esq., Head of the National Healthcare Practice Group, McDonald Hopkins
Learn why lab industry M&A activity is quite different than it was just a year ago. Last year’s hot market has cooled, but talk of a potential economic recovery has lab owners thinking about what their labs might be worth. And lab deals are still being made!
Are you waiting for the market to recover before putting your lab up for sale? Are you thinking about buying a lab? Or do you just need a better understanding of the current market? If you answered yes to any of these questions, you won’t want to miss the new DARK REPORT and DARK DAILY audio conference, “Laboratory and Pathology M&A Activity: How Recent Sales and the Current Economy Could Impact the Value of Your Lab.”
Listen as our panel of respected financial experts gives you a useful review of the 23 lab-industry transactions that occurred during the past 18 months. Gain a better understanding of the nature of recent M&A activity and the varying sizes and types of labs that have been sold. And because we’ll review this activity chronologically, you’ll see for yourself how dramatic the frequency of transactions has changed in recent months.
More important, there are still opportunities for lab sellers and buyers amidst the current economic doom and gloom. That’s because lab deals are still happening. So if you’re thinking about selling your lab, buying a lab or simply raising capital, you definitely have opportunities to consider.
Register for this audio conference today and you’ll come away with a better perspective on what your lab is worth and whether or not this is a good time for you to be thinking about an exit strategy for your lab. Whether you’re a lab company executive or a private-equity investor considering the acquisition of a laboratory business or a lab owner contemplating a sale, this is one conference you won’t want to miss.
THE DARK REPORT AUDIO CONFERENCE AT A GLANCE
COST: $245 per dial-in site or CD (unlimited attendance per site)
ORDER AUDIO CD: Click here or call 1-800-560-6363 toll-free
- Here’s just some of what you’ll learn during this insightful 90-minute conference:
- Complete details of the most important lab transactions in the past 12 months.
- What motivates laboratory buyers and acquirers in today’s economy
- Insider analysis of top-priced lab deals and what drove the higher pricing.
- Your best sources of capital for laboratory acquisition and expansion.
- Three things you can do to maximize the value and sales
- price of your laboratory.
- Secrets of auditing your lab and fixing problems to add value, raise the sales price, and increase cash flow.
- Four focus areas for sellers that support a strong sales price and improve short-term profits before the sale.
- Tips for assembling the best “deal team.”
- Understanding key factors that support high laboratory valuations.
…and much more!
Your audio conference registration includes:
- A site license to attend the conference (invite as many people as you can fit around your speakerphone at no extra charge)
- Downloadable PowerPoint presentations from our speakers
- A full transcript emailed to you soon after the conference
- The opportunity to connect directly with our speaker during the audience Q&A session Register Now! Or for more information, call us toll-free at 800-560-6363.
||Managing Director of Haverford Healthcare Advisors. He provides business valuation and merger and acquisition advisory services to owners of pathology practices and clinical laboratories and other healthcare service companies. For 25 years, Mr. Jahnle has been involved in hundreds of valuation and merger and acquisition advisory projects involving pathology practices and clinical laboratories. He co-founded Haverford Healthcare Advisors in 1994. As a valuation and merger and acquisition advisor for 25 years, Mr. Jahnle originated and completed hundreds of clinical laboratory and pathology practice transactions for his clients. In 2006, Mr. Jahnle was a co-founder of Aurora Diagnostics, LLC, a national anatomic pathology laboratory company. He has a Master of Science degree in Taxation and a B.S. in Commerce and Engineering Sciences both from Drexel University, and is an Accredited Senior Appraiser of the American Society of Appraisers, specializing in business valuation.|
||Doug Brown recently joined Lazard as a Managing Director in the Healthcare Group. Previously, Mr. Brown spent eight years at Wachovia Securities as a managing director in the Healthcare Investment Banking Group. He has worked in the investment banking industry since 1991 and has executed a broad range of advisory and capital-markets transactions in the laboratory services industry. Selected advisory transactions include: the sale of Clinical Pathology Laboratories to Sonic Healthcare, the sale of American Esoteric Laboratories to Sonic Healthcare, and the sale of Berkeley Heartlab to Celera. Prior to Wachovia, Mr. Brown was a Vice President at Salomon Smith Barney in the Healthcare investment banking group. Mr. Brown holds a Master of Business Administration from The Fuqua School of Business at Duke University and earned his Bachelor of Business Administration from The University of Texas at Austin.|
|Richard Cooper, Esq. is Head of the National Healthcare Practice Group of McDonald Hopkins. He also serves on the firm’s Board of Directors. Mr. Cooper has a national health law practice that includes the representation of a large number of laboratories on corporate, regulatory/compliance, contracting, strategic, venture and M&A/joint venture matters. Laboratory clients include both independent and hospital-owned laboratories plus clinical, anatomic and specialty labs. He has been involved in a substantial number of lab M&A/joint venture transactions and frequently counsels clients on strategic planning issues related to preparing labs for sale. He received his JD from Georgetown University.|
ACCENT® Continuing Education Credit
The American Association of Clinical Chemistry (AACC) designates this program for a maximum of 1.5 ACCENT® credit hours towards the AACC Clinical Chemist’s Recognition Award. AACC is an approved provider of continuing education for clinical laboratory scientists in the states of California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, and West Virginia.